This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2011 May;12(5):410-1.

doi: 10.1016/S1470-2045(11)70098-5. Epub 2011 Apr 18.

Subcutaneous bortezomib: a step towards optimised drug use

María-Victoria Mateos¹

Affiliations

PMID: 21507716
DOI: 10.1016/S1470-2045(11)70098-5

Comment

Subcutaneous bortezomib: a step towards optimised drug use

María-Victoria Mateos. Lancet Oncol. 2011 May.

. 2011 May;12(5):410-1.

doi: 10.1016/S1470-2045(11)70098-5. Epub 2011 Apr 18.

Author

María-Victoria Mateos¹

Affiliation

¹ Haematology Department, University Hospital of Salamanca, Salamanca, Spain. mvmateos@usal.es

PMID: 21507716
DOI: 10.1016/S1470-2045(11)70098-5

No abstract available

PubMed Disclaimer

Comment on

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study.
Moreau P, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, Grishunina M, Rekhtman G, Masliak Z, Robak T, Shubina A, Arnulf B, Kropff M, Cavet J, Esseltine DL, Feng H, Girgis S, van de Velde H, Deraedt W, Harousseau JL. Moreau P, et al. Lancet Oncol. 2011 May;12(5):431-40. doi: 10.1016/S1470-2045(11)70081-X. Epub 2011 Apr 18. Lancet Oncol. 2011. PMID: 21507715 Clinical Trial.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information